Foreign Media: The scale of China's biotech outbound licensing has reached a historical high, yet it faces increasingly stringent scrutiny from the United States.
China's innovative drug outbound licensing agreements in the first half of this year were valued at approximately $110 billion, setting a new record. According to analysts at GlobalData in the UK, China has become a crucial hub for global biotechnological innovation; its success not only concerns medical innovation but also strategic aspects such as pharmaceutical supply chain resilience, economic competitiveness, and national security.
The concerns within U.S. policy circles are not aimed at China's scientific capabilities per se, but rather at the perceived threat to America’s own competitiveness and technological leadership. In early July, U.S. lawmakers introduced legislation requiring greater transparency regarding foreign influence in the pharmaceutical industry—viewed as the first step toward reducing dependence on Chinese drugs and medical technologies. This supply chain anxiety echoes previous concerns over reliance on rare earth elements.
Original article: toutiao.com/article/1872019153263744/
Disclaimer: The views expressed in this article are solely those of the author.